La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
EyePoint Pharmaceuticals Gestione
Gestione criteri di controllo 2/4
EyePoint Pharmaceuticals' Il CEO è Jay Duker, nominato in Jan2023, e ha un mandato di 1.58 anni. la retribuzione annua totale è $ 2.92M, composta da 21.1% di stipendio e 78.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.11% delle azioni della società, per un valore di $ 467.28K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.6 anni e 3 anni.
Informazioni chiave
Jay Duker
Amministratore delegato
US$2.9m
Compenso totale
Percentuale dello stipendio del CEO | 21.1% |
Mandato del CEO | 1.6yrs |
Proprietà del CEO | 0.1% |
Durata media del management | 1.6yrs |
Durata media del Consiglio di amministrazione | 3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Aug 15EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 09Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%
Jun 19EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)
May 06More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%
Mar 31EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time
Feb 20Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%
Feb 05Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?
Jan 29Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking
Dec 18These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Dec 13Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
May 14Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking
Apr 17EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space
Aug 30Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Jul 16EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD
Jul 15Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Mar 06EyePoint Pharmaceuticals (NASDAQ:EYPT) Is Using Debt Safely
Sep 24Estimating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Apr 02Analisi delle retribuzioni degli amministratori delegati
Data | Compenso totale | Stipendio | Guadagni aziendali |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$87m |
Mar 31 2024 | n/a | n/a | -US$79m |
Dec 31 2023 | US$3m | US$614k | -US$71m |
Sep 30 2023 | n/a | n/a | -US$100m |
Jun 30 2023 | n/a | n/a | -US$106m |
Mar 31 2023 | n/a | n/a | -US$102m |
Dec 31 2022 | US$2m | US$515k | -US$102m |
Sep 30 2022 | n/a | n/a | -US$78m |
Jun 30 2022 | n/a | n/a | -US$77m |
Mar 31 2022 | n/a | n/a | -US$67m |
Dec 31 2021 | US$3m | US$269k | -US$58m |
Sep 30 2021 | n/a | n/a | -US$54m |
Jun 30 2021 | n/a | n/a | -US$42m |
Mar 31 2021 | n/a | n/a | -US$44m |
Dec 31 2020 | US$53k | n/a | -US$45m |
Sep 30 2020 | n/a | n/a | -US$40m |
Jun 30 2020 | n/a | n/a | -US$52m |
Mar 31 2020 | n/a | n/a | -US$51m |
Dec 31 2019 | US$80k | n/a | -US$57m |
Sep 30 2019 | n/a | n/a | -US$58m |
Jun 30 2019 | n/a | n/a | -US$75m |
Mar 31 2019 | n/a | n/a | -US$98m |
Dec 31 2018 | US$27k | n/a | -US$86m |
Compensazione vs Mercato: La retribuzione totale di Jay ($USD 2.92M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 2.41M ).
Compensazione vs guadagni: La retribuzione di Jay è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Jay Duker (65 yo)
1.6yrs
Mandato
US$2,915,146
Compensazione
Dr. Jay S. Duker, M.D., co-founded Hemera Biosciences Inc. and serves as its Executive Director. He serves as Member of Retina Segment Scientific Advisory Board at Aldeyra Therapeutics, Inc. He served as C...
Gruppo dirigente
Nome | Posizione | Mandato | Compensazione | Proprietà |
---|---|---|---|---|
President | 1.6yrs | US$2.92m | 0.11% $ 556.3k | |
Executive VP & CFO | 4.8yrs | US$1.78m | 0.089% $ 436.4k | |
Interim Head of R&D and Director | less than a year | US$161.67k | 0.021% $ 104.8k | |
Senior Vice President of Manufacturing & Operations | 1.1yrs | Nessun dato | Nessun dato | |
Chief Legal Officer & Company Secretary | 5.8yrs | Nessun dato | Nessun dato | |
Chief People Officer & Senior VP of IT | 5.6yrs | Nessun dato | Nessun dato | |
Senior VP & Chief Commercial Officer | 5.2yrs | US$1.46m | 0% $ 0 | |
Chief Business Officer | less than a year | US$1.61m | 0.026% $ 125.6k | |
Chief Regulatory Officer | 2.4yrs | Nessun dato | Nessun dato | |
Senior Vice President of Program Leadership | 1.1yrs | Nessun dato | Nessun dato | |
Chief Medical Officer | less than a year | Nessun dato | Nessun dato | |
CEO of AION Diagnostics Ltd | no data | US$225.94k | Nessun dato |
1.6yrs
Durata media
58yo
Età media
Gestione esperta: Il team dirigenziale di EYPT non è considerato esperto (durata media 1.6 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
Nome | Posizione | Mandato | Compensazione | Proprietà |
---|---|---|---|---|
President | 1.1yrs | US$2.92m | 0.11% $ 556.3k | |
Interim Head of R&D and Director | 5.8yrs | US$161.67k | 0.021% $ 104.8k | |
CEO of AION Diagnostics Ltd | no data | US$225.94k | Nessun dato | |
Independent Non-Executive Chairman | 6.2yrs | US$214.78k | 0.025% $ 120.8k | |
Independent Director | 5.1yrs | US$171.67k | 0.019% $ 91.6k | |
Executive Vice-Chairman | 7.9yrs | US$3.74m | 0.42% $ 2.1m | |
Independent Director | 5.6yrs | US$180.67k | 0.0035% $ 17.0k | |
Co- Chairman of Scientific Advisory Board | 3yrs | Nessun dato | Nessun dato | |
Member of Executive Scientific Advisory Board | 3yrs | Nessun dato | Nessun dato | |
Co-Chair of Scientific Advisory Board | 3yrs | Nessun dato | Nessun dato | |
Member of Executive Scientific Advisory Board | 3yrs | Nessun dato | Nessun dato | |
Member of Executive Scientific Advisory Board | 3yrs | Nessun dato | Nessun dato |
3.0yrs
Durata media
66yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di EYPT sono considerati esperti (durata media dell'incarico 3 anni).